Eagle Pharmaceuticals inc   (EGRX)
Other Ticker:  
Price: $6.4800 $0.23 3.680%
Day's High: $6.54 Week Perf: 8.18 %
Day's Low: $ 6.16 30 Day Perf: 22.26 %
Volume (M): 134 52 Wk High: $ 32.44
Volume (M$): $ 870 52 Wk Avg: $16.21
Open: $6.24 52 Wk Low: $4.10

 Market Capitalization (Millions $) 85
 Shares Outstanding (Millions) 13
 Employees 261
 Revenues (TTM) (Millions $) 258
 Net Income (TTM) (Millions $) 12
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0

Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals Inc. is a specialty pharmaceutical company that is headquartered in Woodcliff Lake, New Jersey, United States. The company was founded in 2007, and it operates as a subsidiary of Eagle Parent Holdings LLC. It is involved in the development and commercialization of injectable drugs that address unmet medical needs.

Eagle Pharmaceuticals focuses on drugs that are difficult to administer or have a limited shelf life. The company's products are designed to improve the safety, efficacy, and convenience of existing therapies. The company has a dedicated research and development team that works on developing the most innovative drugs.

The company's portfolio of products includes injectable drugs for critical care, oncology, and orphan diseases. Among its most notable products are Ryanodex, a treatment for malignant hyperthermia, and Bendeka/Benqim, a treatment for chronic lymphocytic leukemia. Additionally, it offers injectable drugs for the treatment of pain, infections, and rheumatoid arthritis.

Eagle Pharmaceuticals' business model is based on licensing, developing, and partnering with other pharmaceutical companies to market and distribute its products. The company's primary target is the United States market, but it has operations in Europe, the Middle East, and Asia as well. Its products are marketed through a network of distributors and partners.

The company has partnerships with several pharmaceutical companies, including Teva, Lupin, and Dr. Reddy's Laboratories. Eagle Pharmaceuticals has also established partnerships with academic medical centers and research organizations to advance its drug development program.

In conclusion, Eagle Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of injectable drugs for difficult-to-treat medical conditions. Its innovative products are aimed at improving the safety, effectiveness, and convenience of existing therapies. The company is committed to building strong partnerships with other companies and research organizations to advance its drug development program.

   Company Address: 50 Tice Boulevard Woodcliff Lake 7677 NJ
   Company Phone Number: 326-5300   Stock Exchange / Ticker: NASDAQ EGRX
   EGRX is expected to report next financial results on March 22, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


Riding the Eagle: Impact of the Class Action Lawsuit on Eagle Pharmaceuticals' Future

Published Sat, Feb 3 2024 5:40 PM UTC

In a notable development in the pharmaceutical industry, Pomerantz Law Firm has announced the filing of a class action lawsuit against Eagle Pharmaceuticals Inc. (NASDAQ: EGRX), leading to potentially significant implications for the company?s financial and operational future. Eagle Pharmaceuticals has been a notable name in the pharmaceutical industry, with its corporate in...

Class Action

Navigating Turbulence: Eagle Pharmaceuticals' Class Action Lawsuit, Impacts on Shares, and Path Forward

Published Wed, Dec 27 2023 2:00 AM UTC

Eagle Pharmaceuticals Inc. is a prominent specialty pharmaceutical company known for its focus on developing and commercializing injectable products. However, recent events have led to legal troubles, with a class action lawsuit being filed against the company. This article aims to delve into the details surrounding the lawsuit, its potential implications on Eagle Pharm...

Clinical Study

Revolutionizing Postoperative Care: Amisulpride Takes Center Stage at PGA Conference, Unveiling Exciting Findings on Nausea Management

Published Wed, Dec 6 2023 9:05 PM UTC

Eagle Pharmaceuticals Presents Intriguing Findings on Amisulpride's Efficacy in Postoperative Nausea and Vomiting at PGA Conference
New York City, NY - Medical experts from Eagle Pharmaceuticals showcased groundbreaking research on the post-hoc analysis of Amisulpride at the prestigious 77th PostGraduate Assembly in Anesthesiology (PGA). The FDA-approved drug, marketed a...

Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc Reports Positive Income and Improving Profitability in Fiscal Q2 2023, Though Revenue Declines

For the fiscal second quarter of 2023, Eagle Pharmaceuticals Inc experienced a significant improvement in profitability compared to the same period a year ago. The company's profitability turned positive, with earnings of $0.39 per share, compared to a loss of $-0.74 per share in the previous year. However, profits did fall by -11.36% from the preceding reporting period, where earnings were $0.44 per share.
One area of concern for Eagle Pharmaceuticals Inc was the considerable decline in revenue. The company's revenue receded by -12.801%, reaching $64.65 million in the fiscal second quarter of 2023, compared to $74.14 million in the same period a year ago. Sequentially, revenue also decreased by -2.502%, down from $66.31 million. This deterioration in revenue is concerning, especially when compared to the rest of the Major Pharmaceutical Preparations sector, which posted top-line growth during this period.

Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc. Sees Steep Decline in Top-line and Profitability, Struggles with Revenue per Employee and Ranking

Eagle Pharmaceuticals Inc, an American pharmaceutical company, has reported a decline in its revenue per employee on a trailing twelve month basis. The figure fell to $1,023,146, which is below the company's average number of $793,337. The firm has 261 employees, and among its peers within the healthcare sector, employees of 52 other companies have achieved higher revenue per employee.
Furthermore, the company's overall ranking has deteriorated compared to the fourth quarter of 2022, from 0 to 534. For the January to March 31, 2023 period, the company's income fell sharply by 87.1% to $0.44 per share from $3.41 a year before, and income faded by -27.56% from $0.61 per share in the previous quarter.


Eagle Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com